H5N1 antigen combined with MF59 adjuvant
V87_30
Phase 2 mab completed
Quick answer
H5N1 antigen combined with MF59 adjuvant for Influenza, Human is a Phase 2 program (mab) at Seqirus (Australia) Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Seqirus (Australia) Pty Ltd
- Indication
- Influenza, Human
- Phase
- Phase 2
- Modality
- mab
- Status
- completed